Astellas Pharma Inc. · TSE:4503
Astellas Pharma — J.P. Morgan Healthcare Conference 2019
15 slides from Astellas Pharma's conference presentation, Jan 8, 2019
Slide 1: Delivering and Creating Value for Patients
DELIVERING AND CREATING VALUE FOR PATIENTS J.P. Morgan Healthcare Conference Kenji Yasukawa, Ph.D. President and CEO Astellas Pharma Inc. January 8, 2019
Slide 2: Cautionary Statement Regarding Forward-Looking Information
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING 2 INFORMATION In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These sta
Slide 3: Our Vision
OUR VISON 3 Vision We will achieve sustainable growth by pursuing innovative On the Forefront of Healthcare science to produce medical Change to Turn Innovative Science into solutions that provide VALUE VALUE for Patients to patients Common Definition of Outcomes that matter to patients VALUE* Cost
Slide 4: Three Strategic Goals for Sustainable Growth
THREE STRATEGIC GOALS FOR SUSTAINABLE GROWTH 4 Maximizing Product* VALUE and Continue Strategic Goal 1 Operational Excellence Rx and Strategic Goal 2 Evolving How We Create VALUE - With Focus Area Approach - Improve Rx+ Establish Strategic Goal 3 Developing Rx+ programs non- Rx *Key products and lat
Slide 5: Current and Potential Growth Drivers
CURRENT AND POTENTIAL GROWTH DRIVERS 5 If all succeed, we forecast the potential annual sales from 6 key post-POC products to reach approximately 1 trillion yen in next 10 years. Current growth drivers enzalutamide gilteritinib enfortumab vedotin Earlier stage Acute myeloid leukemia Metastatic uroth
Slide 6: Steady Progress in Accordance with the Strategic Plan
STEADY PROGRESS IN ACCORDANCE WITH THE STRATEGIC 6 PLAN Multiple achievements after the announcement of strategic plan in May 2018 enzalutamide: Expansion to M0 CRPC in US and Europe Regulatory gilteritinib: R/R AML in Japan and US approval (Approval based on interim results) Regulatory roxadustat:
Slide 7: Enzalutamide: Top Line Results from Phase 3 ARCHES Study
ENZALUTAMIDE: TOP LINE RESULTS OBTAINED FROM PHASE 3 7 ARCHES STUDY Pursue further opportunity to expand the indication in earlier stage of prostate cancer M1 HSPC patients The study met its primary n=1,150 endpoint, significantly improving rPFS Randomize The preliminary safety analysis appears
Slide 8: Gilteritinib: Launched in US and Japan in Dec 2018
GILTERITINIB: LAUNCHED IN US AND JAPAN IN DEC 2018 8 First FLT3-targeting agent approved for r/r AML FLT3 + AML patients Inhibit both FLT3-ITD mutation which is associated with poor Low-intensity High-intensity induction chemo prognosis, and FLT3-TKD chemo LACEWING mutation which is associated Pha
Slide 9: Enfortumab Vedotin: Registrational Phase 2 Study Ongoing
ENFORTUMAB VEDOTIN: REGISTRATIONAL PHASE 2 STUDY 9 ONGOING The first and we believe only ADC targeting nectin-4 Nectin-4 is a transmembrane antigen expressed in several tumors including cisplatin cisplatin ineligible eligible urothelial cancer 1st line Using ADC to deliver a cytotoxic agent • CP
Slide 10: Roxadustat: Mode of Action and Its Concept
ROXADUSTAT: MODE OF ACTION AND ITS CONCEPT 10 Potential first-in-class oral treatment for anemia associated with CKD and filed in Japan for patients in dialysis in Sep. 2018 HIF-PH Enzymes HIF-α Degrades Rapidly NORMAL Potential new treatment option that Degradation is oral and reduces the need fo
Slide 11: R&D Strategy: Focus Area Approach
R&D STRATEGY: FOCUS AREA APPROACH 11 Focus on unique combinations of Biology and Modality/Technology Clinical pipeline based on Biology Modality/ Focus Area approach Technology Pathophysiology characterized Versatile technology Cancer immunology ASP8374/PTZ-201: P1 ASP1948/PTZ-329: P1 ASP1951/PTZ-52
Slide 12: Established Capabilities in Regenerative Medicine
ESTABLISHED CAPABILITIES IN REGENERATIVE MEDICINE 12 Acquired capabilities to realize the promise of cell therapy Donor PSC (iPSC/ESC) Desired Cell bank cells Drug 1 substance Logistics Patients 2 3 Development 4 Commercialization 5 Achievement as cell therapy foundation Research Manufacturing Suppl
Slide 13: Snapshot of Astellas Regenerative Medicine Program
SNAPSHOT OF ASTELLAS REGENERATIVE MEDICINE 13 PROGRAM Initiated efforts in ophthalmology and expanding to other organs, using new gene editing technology Development Progress ES UDC Cell/ Program Potential Disease Clinical /iPS Application Pre-clinical P1 P2 Retinal pigment • Dry AMD ES Applicable A
Slide 14: Developing Rx+ Programs
TM DEVELOPING Rx+ PROGRAMS 14 Steady progress and continuing to capture new business opportunities Initiatives to build connections and /Treatment supports networks with technology and Image-guided Diagnosis precision surgery knowledge from various fields • Rx+™ Business: Established US base Astel
Slide 15: Three Strategic Goals for Sustainable Growth
THREE STRATEGIC GOALS FOR SUSTAINABLE GROWTH 15 Maximizing Product* VALUE and Continue Strategic Goal 1 Operational Excellence Rx and Strategic Goal 2 Evolving How We Create VALUE - With Focus Area Approach - Improve Rx+ Establish Strategic Goal 3 Developing Rx+ programs non- Rx *Key products and la
Astellas Pharma — J.P. Morgan Healthcare Conference 2019 on 6ix